Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …

Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …

FLT3 mutations are the most common genomic alteration detected in acute myeloid
leukemia (AML) with a worse clinical prognosis. The highly frequent FLT3 mutations …

Venetoclax (VEN) is now widely used in the treatment of acute myelogenous leukemia
(AML) in elderly patients who are not eligible for intensive remission induction therapy …

Although induction chemotherapy (IC) is the standard of care in medically fit patients with
newly diagnosed acute myeloid leukemia (AML), limited retrospective data indicate that …

Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes
(MDS) is difficult in older patients with comorbidities and high-risk disease factors …

Background In the last decade, many steps forward have been made in acute myeloid
leukemia prognostic stratification, adding next-generation sequencing techniques to the …

Venetoclax (VEN) in combination with hypomethylating agents (HMA) or low-dose
cytarabine has become the standard of care for patients with acute myeloid leukemia (AML) …

The heterogeneity of acute myeloid leukemia (AML), a complex hematological malignancy,
is caused by mutations in myeloid cells affecting their differentiation and proliferation. Thus …

Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in children, and despite
considerable progress in treatment outcomes, relapses still pose significant risks of mortality …